Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc., focuses on solid oral and alternative dosage forms such as creams, gels and ointments. Our core competencies include expertise in controlled-release products, controlled substances and other difficult to formulate products. Using our controlled-release drug delivery technologies and formulation skills we develop bioequivalent versions of selected brand name pharmaceuticals, many of which have technically challenging drug delivery requirements. Our specialty generics portfolio also includes products that require special handling or contain raw materials that are more difficult to source. We recently made significant enhancements to our plant in Hayward, CA to support green and sustainable manufacturing. These technical enhancements have improved our efficiencies, and allow us to continue to ensure that our products are of the highest quality.
We bring value to our customers with innovative products in key therapeutic areas. As of February 7, 2014, we currently market 38 generic pharmaceutical products. The newest products in our portfolio include generic Solaraze® Gel (diclofenac sodium gel 3%), authorized generic Trilipix® (fenofibric acid) delayed release capsules in two strengths, 45 and 135 mgs, non-AB rated generic oxymorphone hydrochloride extended-release tablets and authorized generic Zomig® (zolmitriptan) tablets and oral disintegrating tablets in 2.5 and 5 mgs.
We keep our finger on the pulse of the generics industry through our active involvement with the Generic Pharmaceutical Association (GPhA). The organization focuses on a wide variety of issues that affect the generic industry and works with state and federal lawmakers, the U.S. Food and Drug Administration (FDA) and other stakeholders to ensure that affordable, high quality medicines are available to Americans. Our president, Carole Ben-Maimon, M.D. is past Chairman of the Board. Today she sits on the GPhA Executive Committee and is a board member.
The company continues to invest significantly in research and development. As of February 7, 2014, we have 42 products in various stages of development. We also have 35 ANDA’s pending at the FDA. Many have the potential to be first-to-file or first-to-market opportunities.
Our mission is to ensure the availability of high-quality, affordable generic pharmaceuticals and bring value to our customers while conducting our business with uncompromising integrity and ethics.